Vicuron Will Resubmit Anidulafungin For Invasive Candidiasis Under Separate NDA

Current NDA will focus on esophageal candidiasis indication; Vicuron plans to submit an amendment in second quarter 2005 to address FDA’s concerns about the “approvable” antifungal. Invasive candidiasis NDA filing is slated for third quarter 2005.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet